Literature DB >> 30875278

Neratinib Plus Capecitabine Provides a Glimmer of Hope for a Daunting Disease.

Sara A Hurvitz1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30875278      PMCID： PMC6494353          DOI： 10.1200/JCO.19.00083

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  19 in total

1.  Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer.

Authors:  Sandra M Swain; José Baselga; Sung-Bae Kim; Jungsil Ro; Vladimir Semiglazov; Mario Campone; Eva Ciruelos; Jean-Marc Ferrero; Andreas Schneeweiss; Sarah Heeson; Emma Clark; Graham Ross; Mark C Benyunes; Javier Cortés
Journal:  N Engl J Med       Date:  2015-02-19       Impact factor: 91.245

2.  Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31.

Authors:  Karen A Gelmon; Frances M Boyle; Bella Kaufman; David G Huntsman; Alexey Manikhas; Angelo Di Leo; Miguel Martin; Lee S Schwartzberg; Julie Lemieux; Samuel Aparicio; Lois E Shepherd; Susan Dent; Susan L Ellard; Katia Tonkin; Kathleen I Pritchard; Timothy J Whelan; Dora Nomikos; Arnd Nusch; Robert E Coleman; Hirofumi Mukai; Sergei Tjulandin; Rustem Khasanov; Shulamith Rizel; Anne P Connor; Sergio L Santillana; Judith-Anne W Chapman; Wendy R Parulekar
Journal:  J Clin Oncol       Date:  2015-03-16       Impact factor: 44.544

3.  CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.

Authors:  Xavier Pivot; Alexey Manikhas; Bogdan Żurawski; Ewa Chmielowska; Boguslawa Karaszewska; Rozenn Allerton; Stephen Chan; Alessandra Fabi; Paolo Bidoli; Stefania Gori; Eva Ciruelos; Magdolna Dank; Lajos Hornyak; Sara Margolin; Arnd Nusch; Roma Parikh; Fareha Nagi; Michelle DeSilvio; Sergio Santillana; Ramona F Swaby; Vladimir Semiglazov
Journal:  J Clin Oncol       Date:  2015-01-20       Impact factor: 44.544

4.  Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study.

Authors:  Thomas Bachelot; Gilles Romieu; Mario Campone; Véronique Diéras; Claire Cropet; Florence Dalenc; Marta Jimenez; Emilie Le Rhun; Jean-Yves Pierga; Anthony Gonçalves; Marianne Leheurteur; Julien Domont; Maya Gutierrez; Hervé Curé; Jean-Marc Ferrero; Catherine Labbe-Devilliers
Journal:  Lancet Oncol       Date:  2012-11-02       Impact factor: 41.316

5.  Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Clinical Practice Guideline Update.

Authors:  Sharon H Giordano; Sarah Temin; Sarat Chandarlapaty; Jennie R Crews; Francisco J Esteva; Jeffrey J Kirshner; Ian E Krop; Jennifer Levinson; Nancy U Lin; Shanu Modi; Debra A Patt; Jane Perlmutter; Naren Ramakrishna; Eric P Winer; Nancy E Davidson
Journal:  J Clin Oncol       Date:  2018-06-25       Impact factor: 44.544

6.  Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases.

Authors:  Rachel A Freedman; Rebecca S Gelman; Jeffrey S Wefel; Michelle E Melisko; Kenneth R Hess; Roisin M Connolly; Catherine H Van Poznak; Polly A Niravath; Shannon L Puhalla; Nuhad Ibrahim; Kimberly L Blackwell; Beverly Moy; Christina Herold; Minetta C Liu; Alarice Lowe; Nathalie Y R Agar; Nicole Ryabin; Sarah Farooq; Elizabeth Lawler; Mothaffar F Rimawi; Ian E Krop; Antonio C Wolff; Eric P Winer; Nancy U Lin
Journal:  J Clin Oncol       Date:  2016-02-01       Impact factor: 44.544

7.  Phase Ib/II single-arm trial evaluating the combination of everolimus, lapatinib and capecitabine for the treatment of HER2-positive breast cancer with brain metastases (TRIO-US B-09).

Authors:  Sara Hurvitz; Rashi Singh; Brad Adams; Julie A Taguchi; David Chan; Robert A Dichmann; Aurelio Castrellon; Eddie Hu; Jonathan Berkowitz; Aruna Mani; Brian DiCarlo; Rena Callahan; Ira Smalberg; Xiaoyan Wang; Ivana Meglar; Diego Martinez; Evthokia Hobbs; Dennis J Slamon
Journal:  Ther Adv Med Oncol       Date:  2018-11-09       Impact factor: 8.168

8.  TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases.

Authors:  Rachel A Freedman; Rebecca S Gelman; Carey K Anders; Michelle E Melisko; Heather A Parsons; Anne M Cropp; Kelly Silvestri; Christine M Cotter; Kathryn P Componeschi; Juan M Marte; Roisin M Connolly; Beverly Moy; Catherine H Van Poznak; Kimberly L Blackwell; Shannon L Puhalla; Rachel C Jankowitz; Karen L Smith; Nuhad Ibrahim; Timothy J Moynihan; Ciara C O'Sullivan; Julie Nangia; Polly Niravath; Nadine Tung; Paula R Pohlmann; Robyn Burns; Mothaffar F Rimawi; Ian E Krop; Antonio C Wolff; Eric P Winer; Nancy U Lin
Journal:  J Clin Oncol       Date:  2019-03-12       Impact factor: 44.544

9.  Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer: The NEfERT-T Randomized Clinical Trial.

Authors:  Ahmad Awada; Ramon Colomer; Kenichi Inoue; Igor Bondarenko; Rajendra A Badwe; Georgia Demetriou; Soo-Chin Lee; Ajay O Mehta; Sung-Bae Kim; Thomas Bachelot; Chanchal Goswami; Suryanarayan Deo; Ron Bose; Alvin Wong; Feng Xu; Bin Yao; Richard Bryce; Lisa A Carey
Journal:  JAMA Oncol       Date:  2016-12-01       Impact factor: 31.777

Review 10.  Breast cancer brain metastases: the last frontier.

Authors:  José Pablo Leone; Bernardo Amadeo Leone
Journal:  Exp Hematol Oncol       Date:  2015-11-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.